Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Local Insights

  • Sponsored by AnJie Law Firm
    In the US-China Phase One trade deal signed on January 15 2020, notable agreements on patents mostly relate to pharmaceutical sectors – Articles 1.10, 1.11 and 1.12. It is possible that these articles may also have implications for other sectors, which remains to be seen in the subsequent implementation. In addition, the provisions on judicial enforcement and procedures should benefit all patent owners. More technical issues such as indirect infringement or changes to the judicial review of invalidation decisions are not addressed. This update provides a brief overview of these key changes.
  • Sponsored by AnJie Law Firm
    On December 25 2019, the Supreme Court promulgated amendments of Several Provisions on Civil Evidence Rules (amendments). The amendments, which will come into effect on May 1 2020, have attracted lots of attention from IP practitioners. The rules are expected to improve the accuracy and standardisation of evidence production procedures and balance the burden of proof between litigants. Below are some highlights of the amendments.
  • Sponsored by Hechanova Group
    The TRIPS Agreement, to which the Philippines is a signatory, enables governments of member countries with no capacity to manufacture medicines to import/export cheaper pharmaceutical products via a compulsory licence. These are medicines for which they would otherwise have paid a higher price because of existing patents.